Positron emission tomography/Computed Tomography (PET/CT-scanning) is becoming the most versatile diagnostic tool for early/metastatic cancer detection as well as examination of Parkinson and Alzheimer patients. Nuclear medicine procedures are capable of mapping physiological function and metabolic activity and thereby giving specific information about the organs.
The Project partners TBD-Biodiscovery and PharmIdea have acquired all the competence and experience necessary to enter the PET diagnostic market: production of active ingredients and final dosage drug forms. Both partners are business-driven enterprises with a mission, focusing on both rewarding sales to the customers and making the product available for end-users — oncology and neurology patients in Estonia and Latvia.
The main objective of the Project is to develop a PET-product used in Positron emission tomography-computer tomography (PET-CT) for cancer, Alzheimer or Parkinson diagnostics. This Product will be created as a result of very tight cross-border cooperation between Estonian and Latvian companies TBD-Biodiscovery and PharmIdea. The outcome of the Project is final dosage form of the PET-product with all the documentation package, necessary for its implementation in nuclear medicine centers and hospitals. After the first Product is developed and marketed, TBD and PharmIdea plan to continue the cooperation and develop the next PET-products for oncology studies, studies of Alzheimer and Parkinson disease and seek the marketing channels to reach the hospitals worlwide.